Feasibility of using 18F-ML-10 to monitor cardiotoxicity induced by doxorubicin

HUANG Shiming; CHEN Wei; ZHANG Jinming; MA Yongqiang; YUE Jianlan; LI Yanfeng; and LIN Zhichun

PDF(942 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2017, Vol. 28 ›› Issue (3) : 227-231.

ORIGINAL ARTICLES

Feasibility of using ¹⁸F-ML-10 to monitor cardiotoxicity induced by doxorubicin

HUANG Shiming¹, CHEN Wei¹, ZHANG Jinming², MA Yongqiang³, YUE Jianlan¹, LI Yanfeng¹, and LIN Zhichun¹

Author information +

History +

Abstract

Objective To investigate the feasibility of noninvasive monitoring of doxorubicin-induced cardiotoxicity by radionuclide apoptosis imaging agent ¹⁸F-ML-10.Methods Thirty-six KM mice were randomly and equally divided into control group, low dose (15 mg / kg) model group and high dose (20 mg/kg) model group. The mice in control group were injected with normal saline. Doxorubicin was injected into model group at some dose. After 48 hours, mice were subjected to cardiac ultrasonography and the biodistribution of ¹⁸F-FDG and ¹⁸F-ML-10 was determined with gamma counting. The mice were sacrificed to remove the heart for caspase 3 immunohistochemical detection of myocardial cell apoptosis.Results The left ventricular ejection fraction was significantly lower in low dose group (LVEF=59.49±5.32%) and high dose group (LVEF=52.41±6.47%) than that in control group (LVEF=70.58±5.06%), but the uptake of ¹⁸F-FDG in low dose group (%ID/g=0.50±0.11) and high dose group (%ID/g=15.58±1.92) was significantly lower than that in control group (%ID/g=36.18±3.65).The uptake of apoptotic imaging agent ¹⁸F-ML-10 in low dose group (%ID/g=0.50±0.11) and high dose group(%ID/g=1.10±0.55)was significantly higher than that in control group (%ID/g=0.02±0.02) (P<0.05). Caspase 3 immunohistochemistry showed obvious apoptosis of myocardial cells in model group, which was consistent with the uptake of ¹⁸F-ML-10 in the heart.Conclusions Apoptosis is an important pathway for doxorubicin-induced cardiotoxicity. ¹⁸F-ML-10 may contribute to the detection of doxorubicin-induced myocardial apoptosis.

Key words

doxorubicin / cardiotoxicity / apoptosis / ¹⁸F-ML-10

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

HUANG Shiming, CHEN Wei, ZHANG Jinming, MA Yongqiang, YUE Jianlan, LI Yanfeng, and LIN Zhichun. Feasibility of using ¹⁸F-ML-10 to monitor cardiotoxicity induced by doxorubicin[J]. Medical Journal of the Chinese People Armed Police Forces. 2017, 28(3): 227-231

References

[1] Jean S R, Tulumello D V, Riganti C, et al. Mitochondrial Targeting of Doxorubicin Eliminates Nuclear Effects Associated with Cardiotoxicity[J]. ACS Chem Biol, 2015, 10(9):2007-2015.
[2] 王雅婧, 刘德权, 叶剑桥. 多西他赛与表柔比星联合或序贯化疗治疗局部晚期乳腺癌临床观察[J]. 武警医学, 2014, 25(09):921-923.
[3] Yancy C W, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013, 62(16):e147-239.
[4] Cao Y, Ruan Y, Shen T, et al. Astragalus polysaccharide suppresses doxorubicin-induced cardiotoxicity by regulating the PI3k/Akt and p38MAPK pathways[J]. Oxid Med Cell Longev, 2014, 2014:674219.
[5] Hoglund J, Shirvan A, Antoni G, et al. ¹⁸F-ML-10, a PET tracer for apoptosis: first human study[J]. J Nucl Med, 2011, 52(5):720-725.
[6] Oborski M J, Laymon C M, Lieberman F S, et al. First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy[J]. Brain Behav, 2014, 4(2):312-315.
[7] Hyafil F, Tran-Dinh A, Burg S, et al. Detection of Apoptotic Cells in a Rabbit Model with Atherosclerosis-Like Lesions Using the Positron Emission Tomography Radiotracer ^[18F]ML-10[J]. Mol Imaging, 2015, 14:433-442.
[8] Gardin J M, Siri F M, Kitsis R N, et al. Echocardiographic assessment of left ventricular mass and systolic function in mice[J]. Circ Res, 1995, 76(5):907-914.
[9] Kalam K and Marwick T H. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis[J]. Eur J Cancer, 2013, 49(13):2900-2909.
[10] Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management[J]. CA Cancer J Clin, 2016, 66(4):309-325.
[11] Dodos F, Halbsguth T, Erdmann E, et al. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults[J]. Clin Res Cardiol, 2008, 97(5):318-326.
[12] Ewer M S ,Lenihan D J. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?[J]. J Clin Oncol, 2008, 26(8):1201-1203.
[13] Su H, Gorodny N, Gomez L F, et al. Noninvasive molecular imaging of apoptosis in a mouse model of anthracycline-induced cardiotoxicity[J]. Circ Cardiovasc Imaging, 2015, 8(2):e001952.
[14] Panjrath G S, Patel V, Valdiviezo C I, et al. Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model[J]. J Am Coll Cardiol, 2007, 49(25):2457-2464.
[15] Allen A M, Ben-Ami M, Reshef A, et al. Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with (1)(8)F-ML-10[J]. Eur J Nucl Med Mol Imaging, 2012, 39(9):1400-1408.